Three Dyne ex­ec­u­tives leave as com­pa­ny re­ports new Duchenne drug da­ta

Dyne Ther­a­peu­tics’ new da­ta on its ex­per­i­men­tal Duchenne mus­cu­lar dy­s­tro­phy drug is be­ing over­shad­owed by the de­par­ture of sev­er­al top ex­ec­u­tives.

The biotech

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER